Serial vaccination with the Melan-AMART-126-35 peptide, CpG-B, and complete Freund adjuvant stably expanded tumor-specific CD8+ TSCM cells after 6 months and supported long-term antitumor immunity (216). Here, CD8A is linked to neoplasm.